Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504699 · ClinicalTrials.gov registry record · NA

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

A NA study, sponsored by New York Medical College.

Terminated
Registry status
NA
Development phase
120
Enrollment target

NCT00504699 is a NA study that was terminated before completion, run by New York Medical College. The registered enrollment target is 120 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504699, a NA study, was terminated before completion, sponsored by New York Medical College.

TERMINATED
Registry status
NA
Development phase
120 participants
Enrollment target

Study Summary

Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant. Their fertility can be preserved by stimulating their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian stimulation increase their estrogen levels in blood.this may stimulate their cancer and increase chance for recurrence. If a medicine that prevent estrogen rise is used (letrozole), this may increase the safety of stimulation. In this study we compared ovarian stimulation in breast cancer patients using letrozole with those who did not undergo stimulation and showed that there is no increase risk for recurrence after a median follow up of 2 years

Interventions

  • PROCEDURE Ovarian stimulation in vitro fertilization cryopreservation

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2002-01
Est. Completion 2018-03-01
Phase NA

Sponsor

New York Medical College

47 total trials

What the Registry Record Tells You About NCT00504699

The ClinicalTrials.gov registry entry for NCT00504699 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ovarian stimulation in vitro fertilization cryopreservation is the first listed.

NCT00504699 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00504699 about?

NCT00504699 is a clinical study titled "Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients". Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant. Their fertility can be preserved by stimulating their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian stimulation increase the...

What is the current status of trial NCT00504699?

This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2002-01. Estimated completion is 2018-03-01.

What interventions are being tested in trial NCT00504699?

The interventions under investigation include: Ovarian stimulation in vitro fertilization cryopreservation (PROCEDURE).

Who is sponsoring clinical trial NCT00504699?

This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.